Our vision
Blood-based cancer screening and monitoring for Southeast Asia.
BioNexus Gene Lab Corp. (Nasdaq: BGLC) runs a whole-blood RNA screening laboratory in Malaysia and holds the exclusive license to bring the VitaGuard™ ctDNA monitoring platform to ten ASEAN markets. Its Chemrex subsidiary distributes industrial chemical and composite raw materials.
Company
Nasdaq: BGLCTwo Malaysian businesses.
One exclusive diagnostics license for ten ASEAN markets.
BioNexus Gene Lab Corp. is a Nasdaq-listed company headquartered in Kuala Lumpur. MRNA Scientific operates its whole-blood RNA screening laboratory, and Chemrex distributes industrial chemical and composite raw materials. Through its November 2025 reciprocal equity and licensing transaction with Fidelion Diagnostics, BGLC acquired an approximately 15% interest in Fidelion and exclusive ASEAN rights to VitaGuard™. Regional use remains subject to technical validation, regulatory requirements, laboratory implementation and commercial execution.
Discover the companyBusinesses &
healthcare partnerships
Meet the companies BioNexus operates and the relationships helping extend its reach.
Explore the business →TechnologyDifferent molecular signals. Distinct healthcare questions.
Understand whole-blood RNA screening, cfDNA, ctDNA and the VitaGuard™ molecular residual disease (MRD) pathway.
Explore technology →Latest updates